Intraoperative Kit for AuNP-Tissue Grafts

AuNP 组织移植术中套件

• 批准号: 10773571
• 负责人: David Grant
• 金额: $ 5.5万
• 依托单位: G5 BIOLOGICAL INNOVATIONS L.L.C.
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-20 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10773571
• 关键词: 3D Print; Adverse reactions; Affect; Allografting; Animal Model; Anterior Cruciate Ligament; Anti-Inflammatory Agents; Autologous Transplantation; Award; Biological; Cardiovascular system; Cell Count; Cell Proliferation; Cellularity; Clinical; Collagen; Data; Degenerative polyarthritis; Development; Ensure; Failure; Funding; Goals; Implant; In Situ; In Vitro; Inflammation; Injury; Knee; Knee Injuries; Legal patent; Ligaments; Liquid substance; Marketing; Methodology; Methods; Missouri; Modification; Non-Steroidal Anti-Inflammatory Agents; Operative Surgical Procedures; Orthopedics; Oryctolagus cuniculus; Outcome; Pain; Patients; Performance; Persons; Phase; Phenotype; Placebos; Population; Preparation; Process; Proliferating; Property; Reconstructive Surgical Procedures; Research; Risk; Saline; Second Look Surgery; Sheep; Small Business Technology Transfer Research; Sterility; Structure; Synovial Fluid; Technology; Time; Tissue Grafts; Tissues; United States; Universities; Validation; Vascularization; Xenograft procedure; anterior cruciate ligament reconstruction; anterior cruciate ligament rupture; biofabrication; biomaterial compatibility; bone; design; experience; graft failure; healing; implantation; improved; in vivo; in vivo Model; inflammatory marker; inflammatory milieu; innovation; nanoGold; nanomaterials; nanoparticle; new technology; novel; regenerative; response; technological innovation; technology platform

Project Summary/Abstract - from the Phase I STTR award The proposed technology is an intraoperative kit comprised of a liquid solution which will conjugate gold nanoparticles (AuNPs) to tissue grafts within minutes. Tissue grafts, such as those used in ACL reconstruction surgery, rarely achieve 100% graft assimilation, thereby leading to a host of problems. A potential solution is to modify the grafts in order to enhance integration and reduce inflammation and thus improve clinical outcomes. The innovation of this technology is the development of the intraoperative kit to attach AuNPs to grafts in surgical suite settings. These grafts can be autografts or commercially available allografts, xenografts, or any other natural materials such as collagen or 3D printed tissues. The specific aims of the project will validate the concept of an intraoperative AuNP-tissue conjugation method. Two specific aims will be rigorously pursued, which include 1) optimizing the intraoperative kit method by producing AuNP grafts that reduce inflammation while increasing cellular proliferation via in vitro studies and 2) validating the inflammation modulation ability and cellular proliferation of the modified grafts in an ACL reconstruction in vivo model. Currently, there are no commercial technologies that modify biologic grafts in order to promote remodeling and reduce inflammation. The significance of this research is the development of an intraoperative method to modify biological grafts to improve clinical performance. The PI and sub-contract PI have the expertise to pursue the aims of this STTR Phase 1 proposal; they have years of experience developing nanomaterial-tissue bionanocomposites and have been involved with several start-up companies.

项目摘要/摘要 - 第一阶段STTR奖 所提出的技术是一种术中套件，该套件由液体溶液组成，该溶液将结合黄金 纳米颗粒（AUNP）在几分钟内到组织移植物。组织移植物，例如用于ACL重建的移植物 手术很少获得100％的移植同化，从而导致许多问题。潜在的解决方案是 修改移植物以增强整合和减轻炎症，从而改善临床 结果。这项技术的创新是术中套件的开发，以将AUNP附加到 手术套件设置中的移植物。这些移植物可以是自体移植或商业上的同种异体移植物，异种移植物， 或任何其他天然材料，例如胶原蛋白或3D印刷组织。该项目的具体目标将 验证术中AUNP组织共轭方法的概念。两个具体的目标将严格 追捕，其中包括1）通过产生减少AUNP移植物来优化术中套件 炎症，同时通过体外研究增加细胞增殖，2）验证炎症 在体内ACL重建中，修饰的移植物的调节能力和细胞增殖。 当前，没有商业技术可以修改生物学移植物，以促进重塑和 减少炎症。这项研究的意义是开发一种术中方法来修改 生物移植物以提高临床性能。 PI和分包合同PI具有专业知识来追求 该STTR 1阶段提案的目的；他们有多年的发展纳米材料组织的经验 Bionanocomposites，并参与了几家初创公司。